Observational studyMedicine2025
Therapeutic efficacy of montelukast sodium combined with budesonide in children with cough variant asthma: Impact on FEV1 and FVC levels.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toward Precision Modeling of Cough-Variant Asthma: Standardized Murine Models, Multidimensional Evaluation, and Translational Applications.Journal of asthma and allergy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the therapeutic effect of montelukast sodium combined with budesonide in children with cough variant asthma (CVA) and its influence on the levels of forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). A total of 112 children with CVA treated in our hospital from January 2019 to January 2021 were selected. According to the different treatment methods, they were divided into control group and experimental group, and the clinical data of each group were collected retrospectively. The control group was treated with budesonide, and the study group was treated with Montelukast sodium combined with budesonide. The clinical therapeutic effect, lung function level, adverse reactions and inflammatory factors were compared between the 2 groups. The effective rate in the study group was 92.9%, compared to 73.2% in the control group, with the study group showing significantly higher rates (P < .05). There was no significant difference in pulmonary function index levels between the 2 groups before drug intervention (P > .05), but levels of all indexes improved after treatment. The levels of FEV1, FVC, peak expiratory flow, and FEV1/FVC in the study group were higher than those in the control group (P < .05). The incidence of adverse reactions such as nausea, rash, and headache was 25.0% in the study group and 23.2% in the control group, with no significant difference between the 2 groups (P > .05). Before treatment, there was no significant difference in the levels of inflammatory factors between the 2 groups (P > .05). After treatment, levels of TNF-α, IL-6, and IgE improved in both groups, with the study group showing lower levels than the control group (P < .05). Montelukast sodium combined with budesonide in the treatment of children with CVA enhances the treatment effect, improves pulmonary function, inhibits inflammatory factors, and does not increase adverse drug reactions, making it a valuable treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.